These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35906791)

  • 1. The pharmacology of blinatumomab: state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials.
    Mocquot P; Mossazadeh Y; Lapierre L; Pineau F; Despas F
    J Clin Pharm Ther; 2022 Sep; 47(9):1337-1351. PubMed ID: 35906791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
    Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
    Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
    Le Jeune C; Thomas X
    Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
    Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
    Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
    Dahl J; Mace M; Kantarjian H; Jabbour E
    Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
    Goebeler ME; Bargou R
    Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications.
    Zhu M; Wu B; Brandl C; Johnson J; Wolf A; Chow A; Doshi S
    Clin Pharmacokinet; 2016 Oct; 55(10):1271-1288. PubMed ID: 27209293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
    Halford Z; Coalter C; Gresham V; Brown T
    Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blinatumomab in Practice.
    Lantz J; Pham N; Jones C; Reed D; El Chaer F; Keng M
    Curr Hematol Malig Rep; 2024 Feb; 19(1):1-8. PubMed ID: 38060085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
    Kiyoi H; Morris JD; Oh I; Maeda Y; Minami H; Miyamoto T; Sakura T; Iida H; Tuglus CA; Chen Y; Dos Santos C; Kalabus J; Anderson A; Hata T; Nakashima Y; Kobayashi Y
    Cancer Sci; 2020 Apr; 111(4):1314-1323. PubMed ID: 31971321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
    Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
    Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab for the treatment of acute lymphoblastic leukemia.
    Kaplan JB; Grischenko M; Giles FJ
    Invest New Drugs; 2015 Dec; 33(6):1271-9. PubMed ID: 26383529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
    Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
    J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
    Wilke AC; Gökbuget N
    Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
    Singh A; Dees S; Grewal IS
    Br J Cancer; 2021 Mar; 124(6):1037-1048. PubMed ID: 33469153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Robinson HR; Qi J; Cook EM; Nichols C; Dadashian EL; Underbayev C; Herman SEM; Saba NS; Keyvanfar K; Sun C; Ahn IE; Baskar S; Rader C; Wiestner A
    Blood; 2018 Aug; 132(5):521-532. PubMed ID: 29743179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.